Healthcare Industry Parkinson's Disease Therapeutics Market Trends

Your Catalyst To a Lucrative Business
Parkinson's Disease Therapeutics Market Analysis, Size, Share,
Growth and Forecast to 2019 - Hexa Research
" Growing global prevalence of Parkinson’s disease is
the primary growth driver of the global Parkinson’s
disease therapeutics market owing to the fact the an
increase in the prevalence of this disease directly
widens the target population base for market
players."
The global Parkinson’s Disease Therapeutics Market may expand robustly over the forecast period (2013 to
2019) owing to the introduction of newer therapies for treating this debilitating movement disorder. Non -
invasive neurostimulation device, adipose derived stem cell therapy, and r epetitive magnetic stimulation
device are examples of the latest therapies. The irregular functioning of dopamine producing nerve cells
leads to Parkinson’s disease.
Dopamine regulates & facilitates bodily movements by sending appropriate signals to the br ain. This
hormone also facilitates the smooth functioning of muscles. Main symptoms of Parkinson’s disease are slow
movements, tremors in the limbs, and problems in walking and balancing. In extreme cases, a patient may
have problems in swallowing, suffer from constipation & dementia, and even face speech disabilities.
The worldwide Parkinson’s disease therapeutics Market is segmented on the basis of products and regions.
According to products, the categories are drug therapy, ablative neurosurgery, deep brain stimulation device,
and others. At present, the industry is led by the drug therapy segment in terms of revenues. Patent
expirations of prime drugs, such as Agilect/Azilect and Stalevo/Comtan/Comtess may negatively impact the
growth of this segment in the near future. However, a strong product pipeline may offset revenue losses
because of patent expirations. Key products currently in the pipeline are GlaxoSmithKline’s IPX -066 and EMD
Serono/Merck Serono/Newron Pharmaceutical’s MAO-B inhibitor safinamide. The list also includes Kyowa
Hakko Kirin’s adenosine A2A receptor antagonist istradefylline. End users in the global industry are clinics,
homecare settings, and hospitals.
Browse Details of Report @ https://www.hexaresearch.com/research-report/parkinson-disease-
therapeutics-industry
Follow Us: